A practical reference on Nicotinamide mononucleotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-27. Anything still debated is marked as such rather than presented as settled.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
=== Insulin glargine/lixisenatide === Insulin glargine/lixisenatide, marketed under the brand name Soliqua, is a fixed-dose combination medication that combines insulin glargine and lixisenatide for the treatment of diabetes. The most common side effects include hypoglycemia, diarrhea, vomiting, and nausea. Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017. It is currently only marketed by Sanofi as Soliqua.
The non-essential amino acid arginine, consumed in sufficient amounts, is thought to act as a donor for the synthesis of nitric oxide, a vasodilator. A review confirmed blood pressure lowering. Taurine, a popular dietary supplement ingredient with claims made for sports performance, is technically not an amino acid. It is synthesized in the body from the amino acid cysteine.
=== Laboratory applications === In the laboratory, EDTA is widely used for scavenging metal ions: In biochemistry and molecular biology, ion depletion is commonly used to deactivate metal-dependent enzymes, either as an assay for their reactivity or to suppress damage to DNA, proteins, and polysaccharides. EDTA also acts as a selective inhibitor against dNTP hydrolyzing enzymes (Taq polymerase, dUTPase, MutT), liver arginase and horseradish peroxidase independently of metal ion chelation. These findings urge the rethinking of the utilisation of EDTA as a biochemically inactive metal ion scavenger in enzymatic experiments. In analytical chemistry, EDTA is used in complexometric titrations and analysis of water hardness or as a masking agent to sequester metal ions that would interfere with the analyses. EDTA finds many specialised uses in the biomedical labs, such as in veterinary ophthalmology as an anticollagenase to prevent the worsening of corneal ulcers in animals. In tissue culture, EDTA is used as a chelating agent that binds to calcium and prevents joining of cadherins between cells, preventing clumping of cells grown in liquid suspension, or detaching adherent cells for passaging. In histopathology, EDTA can be used as a decalcifying agent making it possible to cut sections using a microtome once the tissue sample is demineralised. EDTA is also known to inhibit a range of metallopeptidases, the method of inhibition occurs via the chelation of the metal ion required for catalytic activity.
Osteopromotive describes a material that promotes the de novo formation of bone. Osteoconductivity describes the property of graft material in which it serves as a scaffold for new bone growth but does not induce bone growth de novo. This means that osteoconductive materials will only contribute to new bone growth in an area where there is already vital bone. Osteoinductivity describes the property of graft material in which it induces de novo bone growth with biomimetic substances, such as bone morphogenetic proteins. Such materials will contribute to new bone growth in an area where there is no vital bone, such as when implanted into muscle tissue. In contrast, osteopromotive substances will not contribute to de novo bone growth but serve to enhance the osteoinductivity of osteoinductive materials. An example of this is enamel matrix derivative, which serves to enhance the osteoinductive nature of demineralized freeze dried bone allograft (DFDBA).
Sources: en.wikipedia.org
Because common law judges historically gave inadequate remedies for workers who were dismissed, and let employers dictate the terms of dismissal by contract, the Fair Work Act 2009 section 382 contains the right to be "protected from unfair dismissal", if the person is an employee, and under section 383 they have been working for at least 6 months, or one year for an employee of an employer with under 15 staff. Small businesses may have a defence if they comply with the Small Business Fair Dismissal Code. In addition, employees must be covered by an award or enterprise agreement, and have an income below $167,500 in July 2023 (the "high income threshold"). Another exception is that "casual" employees have no rights unless they have a "reasonable expectation of continuing employment by the employer on a regular and systematic basis". In Ponce v DJT Staff Management Services a traffic controller employed through a labour hire firm, and classed as "casual", had unpredictable work shifts and some breaks in work, but was still held to have had work on a regular and systematic basis. Unlike in most high income countries, the Fair Work Act 2009 fails to treat expiry of fixed-term contracts as a dismissal that must be fair. The meaning of dismissal includes termination, or being forced to resign by the employer's conduct, or demotion with a significant reduction of pay or duties.
Handbook for Coroners, police officials, military policemen was written by the Austrian criminal jurist Hans Gross in 1893, and is generally acknowledged as the birth of the field of criminalistics. The work combined in one system fields of knowledge that had not been previously integrated, such as psychology and physical science, and which could be successfully used against crime. Gross adapted some fields to the needs of criminal investigation, such as crime scene photography. He went on to found the Institute of Criminalistics in 1912, as part of the University of Graz' Law School. This Institute was followed by many similar institutes all over the world. In 1909, Archibald Reiss founded the Institut de police scientifique of the University of Lausanne (UNIL), the first school of forensic science in the world. Dr. Edmond Locard, became known as the "Sherlock Holmes of France". He formulated the basic principle of forensic science: "Every contact leaves a trace", which became known as Locard's exchange principle. In 1910, he founded what may have been the first criminal laboratory in the world, after persuading the Police Department of Lyon (France) to give him two attic rooms and two assistants. Symbolic of the newfound prestige of forensics and the use of reasoning in detective work was the popularity of the fictional character Sherlock Holmes, written by Arthur Conan Doyle in the late 19th century. He remains a great inspiration for forensic science, especially for the way his acute study of a crime scene yielded small clues as to the precise sequence of events.
Portal: Prelude - An unofficial prequel to Portal, set before the activation of GLaDOS when scientists used to watch over the test chambers and instruct the test subjects. Portal Reloaded - A mod atop Portal 2 that introduces the ability to place a third portal that sends the player-characters or objects through between the present and a future state of the same test chamber. Actions in the present state will alter the future, though manipulation of the future situation will not impact the present, allowing, for example, for one to bring a weighted cube set in the present from its position in the future, back through the time portal, and use that version of the cube in the present. Portal: Revolution - A mod build on Portal 2 by Second Face Software, in which the player controls an anonymous test subject in the destroyed Aperture Science laboratories. The player is tasked to repair a teleportation device. The mod is set in between the events of Portal and Portal 2. Portal Stories: Mel - A mod build on Portal 2, in which the player controls Mel, a female test subject who is named after a character that Valve had originally designed for Portal 2's cooperative mode. It is a fan-made mod that takes place after the events of Portal and before the events of Portal 2. Prospekt - A fan-made sequel to Half-Life: Opposing Force that follows its protagonist, U.S. Marine Adrian Shepherd, as he is sent to help Gordon Freeman during the "Nova Prospekt" segment of Half-Life 2.
== External links == The MEROPS online database for peptidases and their inhibitors: M13.001 Archived 2019-09-12 at the Wayback Machine Neprilysin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08473 (Neprilysin) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== External links == Cerebral Folate Deficiency - description (2019) on the website of the National Organization for Rare Disorders (NORD). Neurodegeneration due to cerebral folate transport deficiency - description in the OMIM, a catalog of genetically-linked disorders.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.